1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  11:35 2022-08-08 am EDT
10714.00 GBX   -1.40%
08:57aTagrisso plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
AQ
07:18aASTRAZENECA : Gets a Buy rating from JP Morgan
MD
07:05aTAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

COVID SCIENCE-Pausing methotrexate improves booster response; first-trimester of pregnancy vaccination most beneficial

06/30/2022 | 02:22pm EDT

June 30 (Reuters) - The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.

Pausing immunosuppression improves COVID-19 booster response

People taking a commonly-used drug for inflammatory conditions such as rheumatoid arthritis or psoriasis get weaker-than-average protection from COVID-19 vaccines, but stopping the drug for two weeks after a booster dose doubled patients' antibody response in a randomized trial.

UK researchers studied 254 adults receiving methotrexate for their conditions who were about to get their third dose of a vaccine from Pfizer/BioNTech, Moderna , or AstraZeneca. Participants were randomly assigned to interrupt methotrexate treatment for two-weeks after the booster, or to continue taking methotrexate as usual. Blood tests one and three months later showed antibody levels were more than twice as high among patients who paused methotrexate for two weeks as among patients who kept taking it. This was true regardless of methotrexate dose, type of inflammatory disease, type of vaccine, and whether or not patients had ever been infected with SARS-CoV-2. Patients' reports of disease flares were slightly more common in the interruption group, but there was no difference between the groups in seeking healthcare input for flares, and there was no impact on quality of life or general health, the researchers reported on Monday in The Lancet Respiratory Medicine https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(22)00186-2/fulltext.

"Further research is required to assess whether interruption in treatment with other similarly acting immunosuppressive drugs will also enhance vaccine-induced immunity," the researchers said.

First-trimester COVID-19 vaccine particularly beneficial

Pregnant women getting vaccinated against COVID-19 should consider the type and timing of vaccination, new research suggests.

The 158 pregnant women in the study received mRNA vaccines from Moderna or Pfizer/BioNTech or the adenovirus-based vaccine from Johnson & Johnson. As reported on Tuesday in Nature Communications https://www.nature.com/articles/s41467-022-31169-8, the Moderna shot provided subtle advantages over the Pfizer shot in antibody levels and function, and both RNA vaccines induced more potent antibodies than the J&J shot. Immune responses to the shots were stronger when administered in the first or third trimester compared to the second trimester, while the transfer of protective COVID-19 antibodies to the fetus through the placenta was most efficient following first and second trimester vaccination.

When unvaccinated women become pregnant, the U.S. Centers for Disease Control and Prevention advises vaccination as soon as possible to maximize the amount of time during which the mother and fetus are protected from COVID-19. The researchers say their findings show that first-trimester vaccination induces an immune response as good as or better than responses later in pregnancy, along with "high transfer efficiency" of antibodies to the fetus. Furthermore, "maternal and neonatal immunity may be further enhanced by boosting in the third trimester," the researchers said.

Click for a Reuters graphic https://tmsnrt.rs/3c7R3Bl on vaccines in development.

(Reporting by Nancy Lapid; Editing by Bill Berkrot)


© Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.40% 10714 Delayed Quote.23.46%
MODERNA, INC. -2.09% 182.94 Delayed Quote.-26.44%
All news about ASTRAZENECA PLC
08:57aTagrisso plus savolitinib demonstrated 49% objective response rate in lung cancer patie..
AQ
07:18aASTRAZENECA : Gets a Buy rating from JP Morgan
MD
07:05aTAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer pati..
BU
06:55aASTRAZENECA : Enhertu approved in the US as the first HER2-directed therapy for patients w..
PU
05:42aAstraZeneca Says Lung Cancer Combination Therapy Showed 49% Objective Response Rate
MT
05:03aAstraZeneca's Lung Cancer Drug Combo Shows 49% Objective Response Rate in Mid-stage Tri..
MT
04:30aEnhertu approved in the US as the first HER2-directed therapy for patients with HER2-lo..
AQ
02:09aClimate change puts Lyme disease in focus for France's Valneva after COVID blow
RE
12:35aAstraZeneca's Enhertu Breast Cancer Treatment Approved for Use in US
DJ
08/07AstraZeneca's Breast Cancer Drug Wins US FDA's First-in-class Approval
MT
More news
Analyst Recommendations on ASTRAZENECA PLC
More recommendations
Financials (USD)
Sales 2022 44 198 M - -
Net income 2022 4 471 M - -
Net Debt 2022 24 385 M - -
P/E ratio 2022 46,3x
Yield 2022 2,27%
Capitalization 201 B 201 B -
EV / Sales 2022 5,10x
EV / Sales 2023 4,72x
Nbr of Employees 83 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Last Close Price 129,78 $
Average target price 144,13 $
Spread / Average Target 11,1%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Aradhana Sarin Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas NICOLAS Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC23.46%202 796
JOHNSON & JOHNSON0.02%449 879
ELI LILLY AND COMPANY9.09%286 307
PFIZER, INC.-16.56%276 449
ROCHE HOLDING AG-16.46%271 358
ABBVIE INC.1.95%244 068